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Abstract
Background: The efficacy, safety and tolerability of lumiracoxib, a novel selective cyclooxygenase-2
(COX-2) inhibitor, has been demonstrated in previous studies of patients with osteoarthritis (OA). As it
is important to establish the long-term safety and efficacy of treatments for a chronic disease such as OA,
the present study compared the effects of lumiracoxib at doses of 100 mg once daily (o.d.) and 100 mg
twice daily (b.i.d.) with those of celecoxib 200 mg o.d. on retention on treatment over 1 year.
Methods: In this 52-week, multicentre, randomised, double-blind, parallel-group study, male and female
patients (aged at least 40 years) with symptomatic primary OA of the hip, knee, hand or spine were
randomised (1:2:1) to lumiracoxib 100 mg o.d. (n = 755), lumiracoxib 100 mg b.i.d. (n = 1,519) or celecoxib
200 mg o.d. (n = 758). The primary objective of the study was to demonstrate non-inferiority of
lumiracoxib at either dose compared with celecoxib 200 mg o.d. with respect to the 1-year retention on
treatment rate. Secondary outcome variables included OA pain in the target joint, patient's and physician's
global assessments of disease activity, Short Arthritis assessment Scale (SAS) total score, rescue
medication use, and safety and tolerability.
Results: Retention rates at 1 year were similar for the lumiracoxib 100 mg o.d., lumiracoxib 100 mg b.i.d.
and celecoxib 200 mg o.d. groups (46.9% vs 47.5% vs 45.3%, respectively). It was demonstrated that
retention on treatment with lumiracoxib at either dose was non-inferior to celecoxib 200 mg o.d.
Similarly, Kaplan-Meier curves for the probability of premature discontinuation from the study for any
reason were similar across the treatment groups. All three treatments generally yielded comparable
results for the secondary efficacy variables and all treatments were well tolerated.
Conclusion: Long-term treatment with lumiracoxib 100 mg o.d., the recommended dose for OA, was as
effective and well tolerated as celecoxib 200 mg o.d. in patients with OA.
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Background
Osteoarthritis (OA) is the most common arthritis in
adults, with an estimated worldwide prevalence of 9.6%
for men and 18.0% for women aged at least 60 years [1].
The prevalence of OA is particularly high in Europe and
the USA compared with other parts of the world. As a con-
sequence of an increasingly aging population together
with an elevated risk for OA with advancing age, OA will
become an even greater burden in the coming years.
OA is a major cause of impaired mobility that has a seri-
ous detrimental impact on a patient's quality of life and
their ability to perform normal daily activities [2,3].
Indeed, it is associated with a substantial non-fatal burden
of disease, estimated to account for 2.8% of total years of
living with disability [4]. OA is characterised by joint pain,
tenderness, stiffness, crepitus and local inflammation [1]
and most commonly affects the joints of the hip, knee,
hand, foot and spine.
The pharmacological options for treating OA pain include
simple analgesics (e.g. acetaminophen/paracetamol), tra-
ditional nonselective nonsteroidal anti-inflammatory
drugs (NSAIDs) and selective cyclooxygenase-2 (COX-2)
inhibitors [3,5]. Although the efficacy of traditional
NSAIDs for relieving OA pain is well established [6,7],
they can be associated with serious gastrointestinal (GI)
complications [8,9]. NSAID-related gastric damage is
caused by inhibition of cyclooxygenase-1 (COX-1) and
prostaglandins, which help to maintain GI mucosal integ-
rity. Hence, selective COX-2 inhibitors have been devel-
oped to try to minimise these potentially serious GI effects
while providing analgesia comparable with traditional
NSAIDs [10-14].
Lumiracoxib (Prexige®) is a novel selective COX-2 inhibi-
tor developed for the treatment of OA [14-18] and acute
pain, such as dental pain following surgery [19], sprains
and strains [20], primary dysmenorrhoea [21] and acute
flares of gout [22].
As a chronic disease, OA often requires continued man-
agement for extended periods and it is important to estab-
lish the safety and efficacy of treatments in the long term
[3,5]. Moreover, it is difficult to keep many patients on
their OA medications and the majority of patients discon-
tinue treatment after 1 year [23]. Hence, the objective of
this 52-week study was to investigate the long-term effects
of lumiracoxib 100 mg o.d. (the recommended dose in
OA) and lumiracoxib 100 mg twice daily (b.i.d.) com-
pared with celecoxib 200 mg o.d. in patients with OA of
the knee, hand, hip or spine. In order to provide an indi-
cation of overall effectiveness and safety, the primary out-
come variable used in this study was retention on
treatment. Retention on treatment reflects the interrelated
issues of efficacy, safety and tolerability and represents a
relevant measure for assessment in clinical trials.
Methods
Study design
This was a 52-week, multicentre, randomised, double-
blind, double-dummy, active-controlled, parallel-group
study conducted in 65 centres in Europe (Belgium, Ger-
many, France, Italy and Switzerland) and 149 centres in
North America (Canada and the USA). The study received
Ethics Committee approval, was performed in accordance
with the ICH Harmonized Guidelines for Good Clinical
Practice (GCP) and the Declaration of Helsinki, and all
patients provided written, informed consent before the
start of the study.
Following a 3–7-day screening period, during which the
patient's current NSAID therapy was washed out, patients
were randomised (1:2:1) to lumiracoxib 100 mg o.d.,
lumiracoxib 100 mg b.i.d. (twice the recommended dose
in OA) or celecoxib 200 mg o.d. for 52 weeks. Since there
was limited experience with the lumiracoxib 100 mg b.i.d.
dose, twice as many patients were recruited into this treat-
ment arm.
After giving written informed consent, patients were
assigned a unique patient identification number. Ran-
domisation was performed using an interactive voice
response system which collected patient identifying infor-
mation by telephone and assigned randomisation num-
bers linking the patient to a treatment group and
specifying a unique medication number for the study drug
to be dispensed to the patient. A validated and automated
system assigned patient numbers to randomisation num-
bers in a block formation in order to ensure treatment
groups were balanced within centres. A separate medica-
tion randomisation list was produced using a validated
system that automated the random assignment of medica-
tion numbers to medication packs containing each of the
study drugs.
Patients, investigator staff, persons performing the assess-
ments, and data analysts remained blinded to the identity
of the treatment from the time of randomisation until
database lock. A double-blind, double-dummy study
design was used to conceal the identity of treatments by
use of study drugs and respective matching placebos that
were all identical in packaging, labelling, schedule of
administration, and appearance.
Patients
The study recruited male and female patients aged at least
40 years of age with symptomatic primary OA in the hip,
knee, hand or spine (cervical or lumbar) for at least 3
months, and who required NSAID therapy that wasBMC Musculoskeletal Disorders 2008, 9:32 http://www.biomedcentral.com/1471-2474/9/32
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expected to continue for 12 months (with possible single
interruptions of no more than 4 weeks and total interrup-
tions of no more than 3 months). Patients were also
required to have a baseline pain assessment (5-point Lik-
ert scale) of mild, moderate or severe in the target joint.
Patients were excluded if they had: secondary OA with his-
tory and/or any evidence of rheumatoid arthritis (RA),
uncontrolled gout, or inflammatory disease in the target
joint; a history or evidence of infectious arthritis, pseudo-
gout or acute forms of inflammatory gout in the target
joint; hypersensitivity to analgesics, antipyretics or
NSAIDs; peptic ulceration within the last 12 months or
clinically significant GI bleeding within the last 5 years;
hepatic (alanine aminotransferase [ALT] and/or aspartate
aminotransferase [AST] >1.5 × upper limit of normal
[ULN]; bilirubin >1.2 × ULN [unless consistent with Gil-
bert's disease in the opinion of the investigator]), renal,
pancreatic or biliary disease, blood coagulation disorders,
anaemia or platelet count of <100 × 109/L; significant
medical problems, such as uncontrolled hypertension,
symptomatic heart failure; or any other clinically relevant
condition or current medication that in the opinion of the
investigator contra-indicates the use of any of the study or
rescue medications. Pregnant or lactating women or pre-
menopausal women not using an acceptable form of birth
control were ineligible for inclusion, as were patients
using: NSAIDs, except low-dose aspirin (75 mg-100 mg/
day) if taking a stable dose for at least 4 weeks before ran-
domisation and if not taken for secondary prevention of
cardiovascular disease; systemic corticosteroids (except
eye drops, topical or nasal application, or inhaled for
asthma or chronic bronchitis taken at a stable dose for at
least 2 weeks before randomisation); hyaluronic acid
injection or intra-articular corticosteroid in the target joint
in the last month; any drugs known to be contra-indicated
with celecoxib (e.g. lithium, fluconazole, coumarins); or
taking >2 g per day of rescue medication (acetaminophen/
paracetamol) during the screening period. Before the pro-
tocol amendment, patients were ineligible if they had: an
MI, stroke, coronary artery bypass grafting (CABG), inva-
sive coronary revascularisation or new-onset angina
within the 6 months before screening; or a history of cor-
onary heart disease with electrocardiogram (ECG) evi-
dence of silent MI, or congestive heart failure with
symptoms at rest or with minimal activity or unstable
angina. After the study had started, an amendment was
made to the protocol following an announcement of pos-
sible increased CV risk with celecoxib. Consequently,
patients with an elevated CV risk or a history of CV or cer-
ebrovascular disease (i.e. angina pectoris of any severity,
MI, CABG or percutaneous coronary intervention, tran-
sient ischaemic attack, clinically significant carotid artery
stenosis or carotid endarterectomy, ischaemic stroke, or
congestive heart failure NYHA class III-IV) were no longer
eligible to participate in the study. Following the protocol
amendment, patients taking low-dose aspirin for second-
ary prevention of cardiovascular disease were also discon-
tinued, although those patients receiving low-dose aspirin
for at least 4 weeks before screening for other reasons
could continue.
Study objectives and assessments
The study's primary objective was to demonstrate non-
inferiority of lumiracoxib 100 mg o.d. or lumiracoxib 100
mg b.i.d. compared with celecoxib 200 mg o.d. with
respect to the long-term retention rate in patients suffering
from primary OA in hip, knee, hand or spine. The primary
outcome variable was retention on treatment at 1 year; a
patient was considered retained on treatment for 1 year if
the study treatment was not discontinued before Week 50.
As discontinuations can occur due to insufficient efficacy
and/or safety or tolerability issues, retention of patients
on treatment provides a measure of the overall effective-
ness of the treatment. The secondary objectives of the
study were to compare lumiracoxib versus celecoxib with
respect to efficacy (OA pain intensity in the target joint;
patient's global assessment of disease activity; physician's
global assessment of disease activity), reasons for discon-
tinuation, safety and tolerability, and patient-reported
outcomes.
Efficacy was assessed by measuring the following parame-
ters at baseline and at Weeks 4, 13, 20, 26, 39 and 52 using
5-point Likert scales: overall OA pain intensity in the tar-
get joint (1 = none, 2 = mild, 3 = moderate, 4 = severe, 5
= extreme); patient's global assessment of disease activity
(1 = very good, 2 = good, 3 = fair, 4 = poor, 5 = very poor);
physician's global assessment of disease activity (1 = very
good, 2 = good, 3 = fair, 4 = poor, 5 = very poor). Patient-
reported outcomes were analysed using the psychometric
properties of the Short Arthritis assessment Scale (SAS).
Patients completed the SAS, which comprises four 11-
point scales (pain, global, difficulty with stairs and diffi-
culty with shopping), at baseline and at Weeks 13, 26, 39
and 52.
Rescue medication use was recorded for the study dura-
tion. During the treatment phase of the study, a daily max-
imum of 2 g and a maximum cumulative dose of 2 g daily
per two-thirds of the period between two consecutive vis-
its was permitted. Patients exceeding this cumulative dose
between visits were discontinued as having an unsatisfac-
tory therapeutic effect.
Safety and tolerability were evaluated by recording
adverse events (AEs) and serious AEs (SAEs) throughout
the study. Physical examinations were performed at base-
line and Weeks 13, 26, 39 and 52, and laboratory tests
(haematology, blood chemistry, urinalysis) and vital signsBMC Musculoskeletal Disorders 2008, 9:32 http://www.biomedcentral.com/1471-2474/9/32
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were assessed at baseline and Weeks 4, 13, 20, 26, 39 and
52. Elevations in ALT and/or AST >3 × ULN were reported
since this level was considered to be most relevant to
health authorities and healthcare providers. Investigators
were required to report all suspected predefined GI, CV/
cerebrovascular and hepatic events for assessment and
adjudication in a blinded manner by independent safety
committees. The adjudicated CV/cerebrovascular events
were assessed using a composite endpoint defined by the
APTC, which includes CV death, MI and stroke (ischaemic
or haemorrhagic) [24]. APTC events were reported up to
52 weeks after randomisation regardless of whether
patients had discontinued prematurely (these patients
had a follow-up call at 52 weeks). Deaths could be
reported up until just before database lock and were
included in the clinical database regardless of the patient's
date of study completion or premature discontinuation.
All SAEs occurring up to 30 days after the patient's last
dose of study drug were reported to the Clinical Safety and
Epidemiology department, according to standard
Novartis SAE reporting procedures, and were not entered
into the clinical database.
Statistical analysis
Planned enrolment was for 750 patients in each of the
lumiracoxib 100 mg o.d. and celecoxib 200 mg o.d.
groups and 1,500 patients in the lumiracoxib 100 mg
b.i.d. treatment arm. With these sample sizes, a one-sided
test of proportions at the 1.25% level of significance had
98% power to show non-inferiority of lumiracoxib 100
mg b.i.d. to celecoxib 200 mg o.d., and 94% power to
show non-inferiority of lumiracoxib 100 mg o.d. to
celecoxib 200 mg o.d. Assumptions were made that the
retention rates did not differ and were between 45% and
55% (a figure based upon previous experience with other
lumiracoxib studies of 12 months' duration), and that the
non-inferiority margin was -10%.
All efficacy evaluations were performed on the population
of randomized patients who received at least one dose of
study medication, the intention-to-treat (ITT) population.
Non-inferiority of lumiracoxib for the primary outcome
variable (1-year retention on treatment) was tested by a
non-inferiority test comparing pairwise differences using
a multiple testing procedure to adjust for multiplicity and
a confidence interval (CI) approach with a predefined
non-inferiority margin of -10%. The analysis was repeated
for the per protocol population (all ITT patients without
major protocol violations). The data were described by
cumulative Kaplan-Meier estimates at Weeks 4, 13, 20, 26,
39 and 52. Retention on treatment was further explored
by using a multiple logistic regression model with treat-
ment as main effect and age as covariate. The reasons for
discontinuation were also examined.
The secondary efficacy variables, overall OA pain intensity
in the target joint, patient's global assessment of disease
activity and physician's global assessment of disease activ-
ity, were summarised as the weighted average over the
treatment period, representing the overall level of efficacy
experienced, and evaluated using analysis of covariance
(ANCOVA) with treatment as main effect and respective
baseline value, age and centre as covariates. Results were
presented as least squares means (LSM) with 95% CI. In
addition, these variables were classified as 'improved',
'worsened' or 'unchanged' according to changes observed
on the Likert scales from baseline to study endpoint;
'improvement' and 'worsening' were defined as a decrease
and increase by at least one category, respectively.
Improvement rates were compared between treatment
groups by multiple logistic regression analysis (including
treatment as main effect and age as covariate). Missing
baseline assessments were replaced by the median of the
baseline assessments and missing post-baseline data were
imputed using the last observation carried forward
(LOCF) technique. The four SAS scales were added to
form the SAS total score. The analysis included question-
naires with no more than one missing question; missing
values were replaced by the median value for all patients
at the particular timepoint. The SAS total score was ana-
lysed using ANCOVA with treatment as main effect and
baseline value, country and treatment as covariates. Res-
cue medication use was analysed using a multiple logistic
regression model, with baseline pain intensity and treat-
ment as main effects. All statistical tests for the secondary
efficacy variables were performed at the 5% level of signif-
icance without adjusting for multiplicity.
Safety was evaluated in the safety population (all ran-
domised patients who received at least one dose of study
medication), which was identical to the ITT population.
Safety data were analysed and presented using descriptive
statistics.
After completion of the study and database lock, a quality
assurance audit found that one of the participating centres
failed to meet the required standards of clinical practice.
Since the database had been locked including data from
the 63 patients from this centre, a sensitivity analysis was
performed to examine whether exclusion of this data
would significantly change the outcomes from this study.
Results
Between 07 September 2004 and 18 November 2004, a
total of 3,036 patients were enrolled and randomised;
four patients did not receive the study drug and were
excluded from all analyses. Hence, a total of 755, 1,519
and 758 patients were included in the lumiracoxib 100
mg o.d., lumiracoxib 100 mg b.i.d. and celecoxib 200 mg
o.d. treatment arms (ITT/safety population), respectivelyBMC Musculoskeletal Disorders 2008, 9:32 http://www.biomedcentral.com/1471-2474/9/32
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(Figure 1). The per protocol population comprised 648,
1310 and 675 patients randomized to the lumiracoxib
100 mg o.d., lumiracoxib 100 mg b.i.d. and celecoxib 200
mg o.d. treatment arms.
Baseline demographic and background characteristics
were comparable across the treatment groups (Table 1).
The majority of patients were female (71.0%), mean age
was 62.5 ± 10.07 years and mean disease duration was 7.7
± 7.73 years. The distribution of target OA joints assessed
was 48.4% knee, 23.0% spine, 20.6% hand and 7.9% hip.
In the majority of patients (93.3%), pain intensity in the
target OA joint was moderate or severe.
Patient disposition was also similar across the treatment
groups. The percentage of patients completing the study
was 46.9% for lumiracoxib 100 mg o.d., 47.9% for lumi-
racoxib 100 mg b.i.d. and 45.3% with celecoxib 200 mg
o.d. (Figure 1). The main reasons for discontinuation
were administrative problems (13.5–15.7%), AEs (11.7–
12.7%), unsatisfactory therapeutic effect (10.4–12.8%)
and withdrawal of consent (10.3–12.3%) (Figure 1). Fol-
lowing the protocol amendment excluding patients with
an elevated CV risk or history of CV or cerebrovascular dis-
ease, 11.9–13.6% of patients were discontinued for
administrative reasons and 3.3–4.5% withdrew consent.
Retention on treatment
More than 45% of patients in each group remained on
treatment for 1 year. Retention rates were 46.9% for lumi-
racoxib 100 mg o.d., 47.5% for lumiracoxib 100 mg b.i.d.
and 45.3% with celecoxib 200 mg o.d. (Table 2). Treat-
ment comparisons showed that retention rates were com-
parable for lumiracoxib 100 mg o.d. or lumiracoxib 100
Patient disposition Figure 1
Patient disposition. †Following an announcement of a possible increase in CV risk with celecoxib, some patients withdrew 
consent (4%) and some (12.9%) were discontinued after a protocol amendment excluded patients with an elevated CV risk or 
a history of CV or cerebrovascular disease; o.d. = once daily; b.i.d. = twice daily; ITT = intention-to-treat.
Randomised population (n = 3,036)
Celecoxib 200 mg o.d. (n = 759) Lumiracoxib 100 mg o.d. (n = 757) Lumiracoxib 100 mg b.i.d. (n=1,520)
Did not receive study drug (n = 2) Did not receive study drug (n = 1) Did not receive study drug (n = 1)
ITT/safety population (n = 755) ITT/safety population (n = 1519) ITT/safety population (n = 758)
Completed (n = 728; 47.9%)
Discontinuations (n = 402; 53.1%)
Administrative problems  n = 102 (13.5%)
Due to protocol 
amendment† n = 90 (11.9%)
Unsatisfactory therapeutic 
effect n  =  97 (12.8%)
Adverse events  n = 96 (12.7%)
Withdrew consent n = 78 (10.3%)
Due to adverse publicity† n = 25 (3.3%)
Protocol violation  n = 10 (1.3%)
Lost to follow-up  n = 9 (1.2%)
Abnormal laboratory value
or test result  n = 8 (1.1%)
Discontinuations (n = 792; 52.1%)
Administrative problems  n = 226 (14.9%)
Due to protocol 
amendment† n = 199 (13.1%)
Unsatisfactory therapeutic 
effect n  =  158 (10.4%)
Adverse events  n = 187 (12.3%)
Withdrew consent n = 170 (11.2%)
Due to adverse publicity† n = 68 (4.5%)
Protocol violation  n = 22 (1.4%)
Lost to follow-up  n = 7 (0.5%)
Abnormal laboratory value
or test result  n = 16 (1.1%)
No longer required treatment n = 3 (0.2%)
Discontinuations (n = 415; 54.7%)
Administrative problems  n = 119 (15.7%)
Due to protocol 
amendment† n = 103 (13.6%)
Unsatisfactory therapeutic 
effect n  =  88 (11.6%)
Adverse events  n = 89 (11.7%)
Withdrew consent n = 93 (12.3%)
Due to adverse publicity† n = 27 (3.6%)
Protocol violation  n = 10 (1.3%)
Lost to follow-up  n = 8 (1.1%)
Abnormal laboratory value
or test result  n = 5 (0.7%)
No longer required treatment n = 2 (0.3%)
Completed (n = 344; 45.3%) Completed (n = 355; 46.9%)BMC Musculoskeletal Disorders 2008, 9:32 http://www.biomedcentral.com/1471-2474/9/32
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mg b.i.d. compared with celecoxib 200 mg o.d. (Table 2).
Results obtained from the per protocol population were
consistent with these findings (estimated treatment differ-
ences between lumiracoxib 100 mg o.d. or lumiracoxib
100 mg b.i.d. and celecoxib 200 mg o.d. proportions were
0.02 [95% CI: -0.04, 0.08] and 0.02 [95% CI: -0.03, 0.07],
respectively). Hence, retention on treatment with lumira-
coxib at either dose was shown to be non-inferior to
Table 1: Baseline Patient Characteristics (ITT Population)
Lumiracoxib 100 mg o.d. (n = 
755)
Lumiracoxib 100 mg b.i.d. (n = 
1,519)
Celecoxib 200 mg o.d. (n = 
758)
Age (years), mean ± SD 62.9 ± 10.25 62.2 ± 10.02 62.7 ± 10.00
Females, n (%) 541 (71.7) 1081 (71.2) 531 (70.1)
BMI (kg/m2), mean ± SD 29.5 ± 6.41 29.7 ± 6.34 29.8 ± 6.33
Race, n (%)
White/Caucasian 712 (94.3) 1450 (95.5) 731 (96.4)
Black/African American 22 (2.9) 45 (3.0) 13 (1.7)
Hispanic 10 (1.3) 8 (0.5) 11 (1.5)
Other† 11 (1.5) 16 (1.1) 3 (0.4)
Disease duration (years), mean ± 
SD
7.9 ± 7.73 7.6 ± 7.79 7.5 ± 7.62
Target joint, n (%)
Hip 58 (7.7) 122 (8.0) 59 (7.8)
Knee 376 (49.8) 743 (48.9) 350 (46.2)
Hand 159 (21.1) 301 (19.8) 166 (21.9)
Spine 162 (21.5) 353 (23.2) 183 (24.1)
OA pain, n (%)
Mild 48 (6.4) 102 (6.7) 49 (6.5)
Moderate 363 (48.1) 704 (46.3) 346 (45.6)
Severe 343 (45.4) 712 (46.9) 361 (47.6)
Extreme 1 (0.1) 1 (0.1) 2 (0.3)
Patient's global assessment of 
disease activity, n (%)
Very good 2 (0.3) 8 (0.5) 4 (0.5)
Good 94 (12.5) 167 (11.0) 78 (10.3)
Fair 340 (45.0) 711 (46.8) 360 (47.5)
Poor 296 (39.2) 581 (38.2) 287 (37.9)
Very poor 23 (3.0) 51 (3.4) 29 (3.8)
Physician's global assessment of 
disease activity, n (%)
Very good 1 (0.1) 0 (0.0) 2 (0.3)
Good 51 (6.8) 85 (5.6) 45 (5.9)
Fair 371 (49.1) 784 (51.6) 373 (49.2)
Poor 317 (42.0) 618 (40.7) 324 (42.7)
Very poor 14 (1.9) 31 (2.0) 12 (1.6)
Short Arthritis assessment Scale 
(SAS) total score, mean ± SD
22.4 ± 7.81 22.1 ± 7.61 22.3 ± 7.86
o.d. = once daily; b.i.d. = twice daily; BMI = body mass index; ITT = intention-to-treat; SD = standard deviation; †Japanese, other Asian or Pacific 
Islander or other.
Table 2: Treatment Comparisons of the Retention Rate at 1 Year (ITT Population)
Treatment group N Retention rate, n (%) Contrasts Estimated difference (97.5% CI) Outcome
Lumiracoxib 100 mg 755 354 (46.9) Lumiracoxib 100 mg o.d. 0.02 (-0.04, 0.07) Non-inferior
o.d. - celecoxib 200 mg o.d.
Lumiracoxib 100 mg 1519 722 (47.5) Lumiracoxib 100 mg b.i.d. 0.02 (-0.03, 0.07) Non-inferior
b.i.d. - celecoxib 200 mg o.d.
Celecoxib 200 mg 758 343 (45.3)
o.d.
CI = confidence interval; o.d. = once daily; b.i.d. = twice daily; ITT = intention-to-treat.BMC Musculoskeletal Disorders 2008, 9:32 http://www.biomedcentral.com/1471-2474/9/32
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celecoxib 200 mg o.d. Descriptive comparisons of the two
lumiracoxib groups demonstrated that lumiracoxib 100
mg o.d. was non-inferior to lumiracoxib 100 mg b.i.d.
Kaplan-Meier curves for the probability of premature dis-
continuation from the study for any reason were similar
for the three treatment groups (Figure 2). The median
duration of exposure to study drug was lower for celecoxib
(213.5 days) compared with lumiracoxib 100 mg o.d. and
b.i.d. (266.0 and 268.0 days, respectively).
Secondary efficacy variables
The LSM of the overall efficacy measures for the secondary
efficacy variables were generally similar for all three treat-
ments (Table 3). However, for physician's global assess-
ment of disease activity, lumiracoxib 100 mg b.i.d.
showed a small but statistically significant advantage in
LSM over the other two treatments (2.45 vs 2.55 and 2.52
for lumiracoxib 100 mg o.d. and celecoxib 200 mg o.d.; p
< 0.05). In addition, improvement rates at study end were
comparable between the treatment groups for OA pain
intensity, the patient's global assessment of disease activ-
ity and the physician's global assessment of disease activ-
ity (Table 3). No statistically significant differences
between the treatments were observed.
Mean reductions from baseline in SAS scores occurred at
all clinic visits for each of the treatment groups, demon-
strating that patients had less pain, less difficulty going
downstairs and shopping, and were doing better during
treatment. There were no statistically significant differ-
ences between the groups at any timepoint (data not
shown).
The percentage of patients who used rescue medication
during the study was similar across treatment groups
(lumiracoxib 100 mg o.d., 79.5%; lumiracoxib 100 mg
b.i.d., 80.6%; celecoxib 200 mg o.d., 81.3%).
Safety and tolerability
Both lumiracoxib doses were well tolerated, with similar
incidences of AEs and SAEs reported in the three treat-
ment groups (Table 4). Overall, AEs occurred in 72.6% of
patients treated with lumiracoxib 100 mg o.d., 71.0% of
patients receiving lumiracoxib 100 mg b.i.d. and 69.4% of
patients receiving celecoxib 200 mg b.i.d. Infections and
infestations were the most frequently reported AEs by pri-
mary system organ class (32.1–33.4%), followed by GI
disorders (24.8–28.1%) and musculoskeletal and connec-
tive tissue disorders (21.8–23.3%). The 10 most frequent
adverse events are listed in Table 5; headache (10.8–
11.5%) and nasopharyngitis (9.3–10.6%) were the most
common AEs in all treatment groups.
SAEs occurred in 5.4% (n = 41) of patients treated with
lumiracoxib 100 mg o.d., in 4.7% (n = 72) of patients
receiving lumiracoxib 100 mg b.i.d. and 6.3% (n = 48) of
patients receiving celecoxib 200 mg o.d. Overall, 10
deaths were reported before database lock (lumiracoxib
100 mg o.d., n = 2 [0.3%]; lumiracoxib 100 mg b.i.d., n =
7 [0.5%]; celecoxib 200 mg o.d., n = 1 [0.1%]). Of these,
four patients died within 4 weeks of their last dose of
study drug, two in the lumiracoxib 100 mg o.d. group
(cerebrovascular accident [CVA] – not study drug-related
in the investigator's opinion, haematemesis – study drug-
related in the investigator's opinion) and two in the lumi-
racoxib 100 mg b.i.d. group (MI – not study drug-related
in the investigator's opinion, CVA – study drug-related in
the investigator's opinion). Of the other six deaths, which
occurred more than 4 weeks after study drug discontinua-
tion, five were in the lumiracoxib 100 mg b.i.d. group
(CVA; CV failure secondary to pancreatic cancer; progres-
sion of anaplastic astrocytoma; angina/CV death; and sud-
den death/possible arrythmia) and one was in the
celecoxib 200 mg o.d. group (probable CV death). Of
these six deaths, only the angina/CV death in the lumira-
coxib 100 mg b.i.d. group was considered to be study
drug-related in the investigator's opinion.
The incidence of prespecified AEs (including GI events, GI
ulcers, oedema, CV/cerebrovascular events and chest
pain) was similar across treatment groups (lumiracoxib
100 mg o.d., 25.7%; lumiracoxib 100 mg b.i.d., 24.8%;
celecoxib 200 mg o.d., 22.3%). GI events were the most
common prespecified AEs (20–21% in the lumiracoxib
groups, 18% with celecoxib).
Adjudicated GI, CV/cerebrovascular and liver events were
uncommon with all three treatments. Adjudicated GI
events (all suspected occurrences of perforations, ulcers
and bleeding) occurred in 15 (2.0%) patients in the lumi-
Kaplan-Meier estimates of the probability (%) of premature  discontinuation for any reason (ITT population) Figure 2
Kaplan-Meier estimates of the probability (%) of pre-
mature discontinuation for any reason (ITT popula-
tion). o.d. = once daily; b.i.d. = twice daily; ITT = intention-
to-treat.
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racoxib 100 mg o.d. group, 17 (1.1%) in the lumiracoxib
100 mg b.i.d. group and 10 (1.3%) in the celecoxib 200
mg o.d. group. Symptomatic ulcers were observed in
fewer patients treated with lumiracoxib 100 mg o.d. (n =
1 [0.1%]) or lumiracoxib 100 mg b.i.d. (n = 2 [0.1%])
compared with celecoxib 200 mg o.d. (n = 3 [0.4]). The
incidence of definite or probable upper or lower GI tract
ulcer complications was very low (lumiracoxib 100 mg
o.d. 0.26%, lumiracoxib 100 mg b.i.d. 0.13% and
celecoxib 200 mg o.d. 0.26%). None of the suspected
upper GI tract complications were confirmed as definite
by the independent safety committee. Probable upper GI
tract ulcer complications were reported with lumiracoxib
100 mg b.i.d. (n = 1; haematochezia with signs of bleed-
ing) and celecoxib 200 mg o.d. (n = 1; laboratory evidence
of bleeding). The safety committee adjudicated two lower
GI tract ulcer complications as definite (one case of hae-
matochezia or melena resulting from bleeding in the large
bowel reported as a suspected study drug-related SAE in
the lumiracoxib 100 mg o.d. group, and one case of small
bowel obstruction reported as an AE causing discontinua-
tion in the celecoxib 200 mg o.d. group).
Table 3: Improved OA Pain Intensity and Patient's and Physician's Global Assessments of Disease Activity (ITT Population)
Lumiracoxib 100 mg o.d. (n = 
755)
Lumiracoxib 100 mg b.i.d. (n = 
1,519)
Celecoxib 200 mg o.d. (n = 
758)
Patient's target joint pain intensity 
assessment
Changes in scores from 
baseline to study endpoint, n 
(%)†
Improvement 382 (50.6) 795 (52.3) 406 (53.6)
No change 269 (35.6) 566 (37.3) 265 (35.0)
Worsened 104 (13.8) 158 (10.4) 87 (11.5)
Overall measure of efficacy, 
least squares mean‡
2.78 2.72 2.77
Patient's global assessment of 
disease activity
Changes in scores from 
baseline to study endpoint, n 
(%)†
Improvement 368 (48.7) 768 (50.6) 373 (49.2)
No change 265 (35.1) 534 (35.2) 269 (35.5)
Worsened 122 (16.2) 216 (14.2) 116 (15.3)
Overall measure of efficacy, 
least squares mean‡
2.61 2.54 2.60
Physician's global assessment of 
disease activity
Changes in scores from 
baseline to study endpoint, n 
(%)†
Improvement 411 (54.5) 888 (58.5) 425 (56.2)
No change 244 (32.4) 463 (30.5) 232 (30.7)
Worsened 99 (13.1) 167 (11.0) 99 (13.1)
Overall measure of efficacy, 
least squares mean‡
2.55 2.45* 2.52
o.d. = once daily; b.i.d. = twice daily; ITT = intention-to-treat; †patients with missing baseline values were not included; ‡Overall measure of efficacy 
defined as the weighted average of post-baseline scores using the last observation carried forward technique for missing values and time since 
previous visit as weight (lower scores represent better responses); *p < 0.05 vs lumiracoxib 100 mg o.d. and celecoxib 200 mg o.d.
Table 4: Summary of AEs and SAEs (Safety Population)
Lumiracoxib 100 mg o.d. (n = 
755)
Lumiracoxib 100 mg b.i.d. (n = 
1,519)
Celecoxib 200 mg o.d. (n = 
758)
Patients with AEs, n (%) 548 (72.6) 1078 (71.0) 526 (69.4)
Patients with SAEs, n (%) 41 (5.4) 72 (4.7) 48 (6.3)
Fatal, n (%)† 2 (0.3) 7 (0.5) 1 (0.1)
Discontinuations due to AEs, n (%) 98 (13.0) 193 (12.7) 87 (11.5)
o.d. = once daily; b.i.d. = twice daily; AEs = adverse events; SAEs = serious adverse events; †all deaths occurring before database lock are included.BMC Musculoskeletal Disorders 2008, 9:32 http://www.biomedcentral.com/1471-2474/9/32
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The number of patients with confirmed or probable CV/
cerebrovascular events, defined using the APTC endpoint,
was 3 (0.40%) with lumiracoxib 100 mg o.d., 6 (0.39%)
with lumiracoxib 100 mg b.i.d. and 2 (0.26%) with
celecoxib 200 mg o.d. The event analysis by time interval
is shown in Table 6. The number of patients with con-
firmed or probable APTC events up to Week 52, regardless
of study drug discontinuation, was 4 (0.53%) with lumi-
racoxib 100 mg o.d., 10 (0.66%) with lumiracoxib 100
mg b.i.d. and 5 (0.66%) with celecoxib 200 mg o.d.
ALT/AST elevations >3 × ULN occurred at a higher fre-
quency in patients treated with lumiracoxib 100 mg b.i.d.
(twice the recommended dose) (n = 35 [2.3%]) than with
lumiracoxib 100 mg o.d. (n = 11 [1.5%]) or celecoxib 200
mg o.d. (n = 3 [0.4%]). The type of injury was usually
hepatocellular with some mixed and very few cases of
pure cholestatic liver injury. The majority of patients
affected were asymptomatic and none were clinically
jaundiced. No 'Hy's' cases (ALT/AST >5 × ULN and
bilirubin >3 mg/dL), which are more predictive for severe
liver outcome, were observed with lumiracoxib 100 mg
o.d., and one case was observed with lumiracoxib 100 mg
b.i.d. after 143 days of treatment. An analysis by time
intervals was performed and showed that, after short-term
treatment (1–49 days), no cases of ALT/AST >3 × ULN
were observed with lumiracoxib 100 mg o.d. (0.00%)
compared with 4 (0.26%) with lumiracoxib 100 mg b.i.d.
and 1 (0.13%) with celecoxib 200 mg o.d. (Table 6). The
peak in the incidence of transaminase elevations with
lumiracoxib was observed after 3 to 6 months of treat-
ment (between 106 to 196 days) (Table 6) and then sub-
sided at later timepoints. After >287 days of treatment, the
incidence rates of ALT/AST <3 × ULN decreased to 0.28%
with lumiracoxib 100 mg o.d. and 0.14% with lumira-
coxib 100 mg b.i.d.). Patients with an AST and/or ALT
value between greater than 3 × ULN and less than 5 × ULN
could continue on treatment but liver function tests were
to be repeated within 2 weeks and patients with a value
greater than or equal to the previous value at repeat testing
were immediately discontinued. An AST and/or ALT value
of between greater than 3 × ULN and less than 5 × ULN
was reported in 1.1% of the lumiracoxib 100 mg o.d.
group, 0.8% of the lumiracoxib 100 mg b.i.d. group and
0.4% of the celecoxib 200 mg o.d. group; the median
times to normalization, i.e. when both AST and ALT had
returned to less than 2 × ULN, were 16, 20 and 14 days,
respectively. Patients with elevated liver enzymes were dis-
continued from treatment if AST or ALT values were
greater than 5 × ULN, which occurred in 0.4% of the lumi-
racoxib 100 mg o.d. group, 1.8% of the lumiracoxib 100
mg b.i.d. group and no patients in the celecoxib 200 mg
o.d. group. The time to normalization for ALT/AST values
> 5 × ULN ranged between 4 and 132 days. For those
patients who discontinued due to abnormal liver function
tests, follow-up values were available for all but one
patient (who died due to a cerebrovascular accident) and
transaminase levels were consistently shown to return to
normal or close to normal. Of note, a small number of
patients in each treatment group had abnormal liver func-
tion tests (ALT/AST >1.5 ULN or bilirubin >1.2 × ULN) at
screening and should have been excluded: 0.9% of
patients in the lumiracoxib 100 mg o.d. group, 0.8% of
the lumiracoxib 100 mg b.i.d. group and 0.3% in the
celecoxib 200 mg o.d. group.
The incidences of notable abnormalities of haematology,
biochemistry, urinalysis and vital signs were low and gen-
erally similar across treatment groups. New-onset changes
in renal function (>35.36 µmol/L [0.4 mg/dL] increase in
creatinine level from baseline was chosen as a marker for
renal AEs by the Data Safety Management Board [DSMB])
occurred in 16 patients (2.1%) treated with lumiracoxib
100 mg o.d., 26 patients (1.7%) receiving lumiracoxib
100 mg b.i.d. and five patients (0.7%) treated with
celecoxib 200 mg o.d. Notable increases in blood pres-
sure, pulse or weight tended to occur less frequently with
lumiracoxib 100 mg o.d. than in the other two groups.
Table 5: The 10 Most Frequent AEs (Safety Population)
Lumiracoxib 100 mg o.d.
 (n = 755)
Lumiracoxib 100 mg b.i.d. 
(n = 1,519)
Celecoxib 200 mg o.d. 
(n = 758)
Headache 82 (10.9) 174 (11.5) 82 (10.8)
Nasopharyngitis 80 (10.6) 141 (9.3) 75 (9.9)
Back pain 46 (6.1) 87 (5.7) 52 (6.9)
Arthralgia 53 (7.0) 82 (5.4) 41 (5.4)
Abdominal pain upper 42 (5.6) 88 (5.8) 35 (4.6)
Upper respiratory tract infection 36 (4.8) 86 (5.7) 43 (5.7)
Dyspepsia 38 (5.0) 85 (5.6) 39 (5.1)
Urinary tract infection 38 (5.0) 75 (4.9) 24 (3.2)
Sinusitis 21 (2.8) 58 (3.8) 34 (4.5)
Influenza 30 (4.0) 53 (3.5) 28 (3.7)
o.d. = once daily; b.i.d. = twice daily.BMC Musculoskeletal Disorders 2008, 9:32 http://www.biomedcentral.com/1471-2474/9/32
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Mean changes from baseline in systolic blood pressure
were -2.2 mmHg with lumiracoxib 100 mg o.d., 0.1
mmHg with lumiracoxib 100 mg b.i.d. and -0.3 mmHg
with celecoxib 200 mg o.d. The corresponding changes
from baseline for diastolic blood pressure were -1.1%, -
0.5% and -0.1%. No patients in the lumiracoxib 100 mg
o.d. group experienced a notable increase in pulse rate
(increase from baseline of ≥ 15% and value of ≥ 110 bpm)
compared with 0.2% and 0.3% in the lumiracoxib 100 mg
b.i.d. and celecoxib 200 mg o.d. groups, respectively.
Weight increases of over 5% from baseline were reported
by 10.2% of the lumiracoxib 100 mg o.d. group, 13.8% of
the lumiracoxib 100 mg b.i.d. group and 11.2% of the
celecoxib 200 mg o.d. group.
Sensitivity analysis
In the sensitivity analysis excluding data from the centre
with major violations of GCP, there were no clinically rel-
evant differences from the total ITT population for any
efficacy variable. One-year retention rates for the ITT pop-
ulation excluding the 63 patients from this centre were
comparable with those for the total ITT population, and
there were no differences between these populations in
Kaplan-Meier estimates for the probability of premature
discontinuation from the study for any reason.
A total of 10 of the 63 patients from the excluded centre
reported AEs. Overall, proportions of patients with any AE
or with specific AEs were similar to the total safety popu-
lation. However, two of the patients from this centre were
reported to have notable increases in liver function tests.
Excluding the centre that was audited, the incidence of
ALT/AST elevations (>3 × ULN) probably or possibly
related to study drug was 1.4% with lumiracoxib 100 mg
o.d., 2.3% with lumiracoxib 100 mg b.i.d. (twice the rec-
ommended dose), and 0.4% with celecoxib 200 mg o.d.
Discussion
This large, randomised, double-blind study has demon-
strated that lumiracoxib 100 mg o.d., the recommended
dose for OA, was non-inferior to celecoxib 200 mg o.d. for
retention on treatment at 1 year in patients with OA of the
knee, hip, hand and spine. As this outcome variable is
dependent on the number of treatment discontinuations,
which mainly occur for insufficient efficacy and tolerabil-
ity issues, it indicates that the overall efficacy and safety of
lumiracoxib 100 mg o.d. is comparable with that of
celecoxib 200 mg o.d. Similar findings were observed with
lumiracoxib at the higher dose of 100 mg b.i.d. Previous
studies have reported that discontinuation rates are lower
with selective COX-2 inhibitors compared with tradi-
tional NSAIDs, such as ibuprofen and naproxen [23,25].
These observations could suggest that COX-2 inhibitors
have a more favourable balance of both efficacy and toler-
ability compared with NSAIDs.
Both doses of lumiracoxib were associated with improve-
ments similar to celecoxib in all secondary efficacy param-
eters. At Week 52, approximately 50% of patients in each
treatment group assessed their OA target joint pain and
disease activity to be reduced, with over half of physicians
also reporting lower disease activity. SAS scores were
improved in all three treatment groups and there were no
statistically significant between-group differences in the
use of rescue medication. Although the use of rescue med-
ication was high across all three treatment groups, this
would not be unexpected in a 1-year study.
Table 6: Time to events for elevations in hepatic transaminases and APTC events (Safety Population)
Lumiracoxib 100 mg o.d. (n = 755) Lumiracoxib 100 mg b.i.d. (n = 
1,519)
Celecoxib 200 mg o.d. (n = 758)
Time interval 
(days)
No. of subjects 
with events within 
the interval
Incidence rate 
within the 
interval (%)
No. of subjects 
with events within 
the interval
Incidence rate 
within the 
interval (%)
No. of subjects 
with events within 
the interval
Incidence rate 
within the 
interval (%)
AST/ALT >3 × ULN
1 – 49 0 0.00 4 0.26 1 0.13
50 – 105 1 0.15 7 0.53 1 0.15
106 – 196 6 1.15 18 1.64 1 0.19
197 – 287 3 0.76 5 0.63 0 0.00
> 2 8 7 10 . 2 810 . 1 400 . 0 0
Definite/probable APTC events
1 – 49 0 0.00 1 0.07 0 0.00
50 – 105 0 0.00 1 0.07 1 0.13
106 – 196 1 0.13 1 0.07 0 0.00
197 – 287 1 0.13 3 0.20 1 0.13
> 2 8 7 10 . 1 300 . 0 000 . 0 0
o.d. = once daily; b.i.d. = twice daily.BMC Musculoskeletal Disorders 2008, 9:32 http://www.biomedcentral.com/1471-2474/9/32
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Lumiracoxib 100 mg o.d. was also shown to be as well tol-
erated as celecoxib 200 mg o.d. in this large group of
patients with OA over 1 year. The overall incidence and
type of AEs for lumiracoxib at both doses were compara-
ble with those observed with celecoxib 200 mg o.d., and
as expected given the duration of the study and the popu-
lation studied.
The incidence of adjudicated CV/cerebrovascular events
was very low across the treatment arms, supporting previ-
ous findings that lumiracoxib has a low risk of CV events
that is comparable with NSAIDs. In TARGET, the inci-
dence of non-fatal and silent MI, stroke, or CV death with
lumiracoxib 400 mg o.d. was comparable with that
observed with traditional NSAIDs, ibuprofen and
naproxen [26]. Moreover, a meta-analysis of lumiracoxib
studies with 34,668 patients has also reported that the risk
of CV events with lumiracoxib was not statistically signif-
icantly different from placebo, naproxen or non-naproxen
NSAIDs [27]. These findings are in keeping with a recent
meta-analysis, which has also indicated that the risk of CV
events with selective COX-2 inhibitors is similar to that
observed with most NSAIDs [28]. Another systematic
review and meta-analysis of observational studies has
noted some differences in CV risk with individual NSAIDs
and selective COX-2 inhibitors: there was no elevation in
CV risk with celecoxib, naproxen or ibuprofen, but
rofecoxib and diclofenac were associated with a signifi-
cantly increased risk of serious CV events [29]. These find-
ings support lumiracoxib as a selective COX-2 inhibitor
with a CV risk profile comparable with most other
NSAIDs. Other studies have indicated that lumiracoxib
has a blood pressure profile similar to placebo [30] and
superior to traditional NSAIDs [26,31], which support its
CV safety profile.
Lumiracoxib is indicated at a dose of 100 mg o.d. for
chronic use in OA, and at doses of 200 mg or 400 mg o.d.
for short-term use in acute pain indications. While liver
toxicity is a known rare but serious side effect of all COX-
2 inhibitors and traditional NSAIDs [32], there have been
some specific concerns from health authorities regarding
the hepatic profile of lumiracoxib. Australia withdrew
lumiracoxib in August 2007 following reports of severe
liver events occurring predominantly at doses higher than
lumiracoxib 100 mg o.d. taken chronically. The US FDA
issued a non-approvable letter in September 2007, citing
concerns over the hepatic profile of lumiracoxib. This was
followed by withdrawals in Canada, Europe and a few
other countries. Assessment of the benefit-risk profile of
the drug is ongoing by a number of health authorities. In
this analysis, elevations in liver enzymes of more than 3 ×
ULN, submitted for adjudication and considered to be
related to the study drug, occurred in 1.5% of patients
treated with lumiracoxib 100 mg o.d. This incidence is
greater than previously observed for ALT/AST elevations
>3 × ULN with lumiracoxib 100 mg o.d. in long-term clin-
ical trials (0.91%) (Novartis: data on file, Studies 2360
[core plus extension] and 2361 [core plus extension]
pooled). However, the incidence rate for lumiracoxib 100
mg o.d. is similar to that reported in the prescribing infor-
mation for many NSAIDs (1% or less), such as naproxen
and ibuprofen [33,34], and less than that observed with
diclofenac, which has been associated with ALT and AST
abnormalities in 3.2% and 1.8% of patients, respectively
[35]. It is also important to note that it is very rare for the
elevations in liver enzymes with NSAIDs to translate into
SAEs [36]. Moreover, as shown in this study, elevations in
liver function tests are generally reversible when treatment
is discontinued. Given the increased incidence of ALT/AST
elevations and the lack of additional efficacy benefit with
lumiracoxib 100 mg b.i.d., it would not be advisable to
exceed the recommended dose of lumiracoxib (100 mg
o.d.) for the long-term treatment of OA.
Given that OA pain may require treatment over extended
periods of time, these findings demonstrating that lumira-
coxib is efficacious and well tolerated over 1 year are
important. The long-term efficacy, safety and tolerability
profile of lumiracoxib 100 mg o.d. compared with
celecoxib 200 mg o.d. has also been evaluated previously
in a 39-week, double-blind extension to a 13-week, mult-
icentre, randomised, double-blind, placebo-controlled
trial of patients with knee OA [16,37]. Comparable
improvements were seen for both treatments at all time-
points in all three efficacy variables: OA pain intensity,
patient's global assessment of disease activity and Total
score of the Western Ontario and McMaster Universities
(WOMAC™) Osteoarthritis Index LK 3.1 questionnaire
[16,37]. Furthermore, the incidence and type of AEs
reported were similar between celecoxib 200 mg o.d. and
lumiracoxib 100 mg o.d. [16,37] and elevations in liver
enzymes were in line with previously reported incidence
rates with NSAIDs.
One limitation of this study was related to an announce-
ment after the study had started that there may be a possi-
ble increase in CV risk with celecoxib. To ensure patient
safety, a protocol amendment to patient eligibility was
implemented and 17% of randomised patients, who had
an elevated CV risk, had to be discontinued. Although this
accounted for a significant proportion of treatment dis-
continuations, similar to that attributed to insufficient
efficacy or AEs, supportive analyses showed that this did
not affect the relative distribution for retention on treat-
ment across the treatment arms (data not shown). A sec-
ond limitation of this study was the inclusion of patients
from a centre that did not meet the required standards of
clinical practice. However, a sensitivity analysis demon-
strated that exclusion of data from this centre resulted inBMC Musculoskeletal Disorders 2008, 9:32 http://www.biomedcentral.com/1471-2474/9/32
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the efficacy and safety data similar to that observed for the
total ITT population.
Conclusion
In conclusion, these data show that lumiracoxib 100 mg
o.d. was as effective and well tolerated as celecoxib 200
mg o.d. during long-term treatment of up to 1 year in
patients with OA. Hence, lumiracoxib should be consid-
ered as a useful treatment option for the relief of OA pain.
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